Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

Relapsed Multiple Myeloma Patients Achieve Responses with Single-Agent Carfilzomib

Keith Stewart, M.B., Ch.B., Professor, Division of Hematology/Oncology at the Mayo Clinic, Arizona presented positive data from an ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients. Patients in the study have relapsed after receiving one to three prior therapies and are stratified according to prior exposure to bortezomib.

A total of 31 patients have been enrolled in the Phase 2 clinical trial to date, of which 45 percent had no prior bortezomib experience and 55 percent relapsed following bortezomib treatment. In both arms, substantial response rates were achieved and sustained. Bortezomib-naive patients achieved an overall response rate of 57 percent with a median duration of response of 8.5 months. The median time to progression in this cohort has not been reached.

Among patients with prior bortezomib exposure, 18 percent achieved partial responses and the median duration of response has not yet been reached in this population. The median time to progression for patients in this cohort was 8.9 months. Ten additional patients achieved stable disease.

"Carfilzomib monotherapy achieves durable responses in relapsed multiple myeloma patients regardless of their prior exposure to bortezomib, and notably, a number of patients remain progression free after twelve cycles," said Dr. Stewart.
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
... Call Tomorrow (Tuesday) at 8:30 am EDT to ... Discuss the Clinical ... (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) today announced,the initiation ... norepinephrine reuptake inhibitor (SNRI) - for the treatment of,diabetic neuropathic pain. ...
... CeloNova BioSciences, Inc.,("CeloNova"), a leading developer of ... fully color-coded line of embolic particles,Embozene(TM) Color-Advanced ... and Interventional Radiology Society of Europe (CIRSE) ... ) Embolic microspheres are used to ...
... 7 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... to present a corporate overview at the,ThinkEquity Partners, G5: ... p.m. Eastern Time (10:30 a.m. Pacific Time) at the ... the live audio broadcast or the subsequent archived,recording, log ...
Cached Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7CeloNova BioSciences Announces World's First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres 2Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2
(Date:8/19/2014)... ) -- Scientists at the Houston Methodist Research Institute ... single cells using a pipette -- a common laboratory ... feat and preliminary test results in a recent issue ... . , "Studying single cells and their unique functions ... nanomedicine department. faculty member Lidong Qin, Ph.D., the project,s ...
(Date:8/19/2014)... and other science courses are increasingly being asked ... they have a new textbook to help them ... this month by Princeton Press and co-authored by ... Biological Synthesis (NIMBioS), teaches readers about basic mathematical ... explore and explain biological phenomena. , Suitable for ...
(Date:8/19/2014)... Anyone who has ever had a glass of fizzy ... the air. But in a finding with wide industrial ... push some particles down into the liquid as well. ... aerosol droplets, so we were surprised, and fascinated, to ... the same process injected tiny oil droplets into the ...
Breaking Biology News(10 mins):Moving single cells around -- accurately and cheaply 2New textbook introduces undergraduates to mathematics for the life sciences 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... ( Lepilemur sahamalazensis ), other than the fact it roosts ... holes, and therefore risks falling victim to predators from both ... kept in any zoo. Prior to this research virtually ... that it has been classified as Critically Endangered, the top ...
... study published today in the journal Gondwana Research ... Antarctic and Indian tectonic plates, demonstrating how they formed ... from Royal Holloway University, The Australian National University and ... how the plates evolved and where they should be ...
... years, pilots flying into combat have jammed enemy radar to ... moths can do it, too. A new study co-authored ... pulses from their genitals to respond to bats producing the ... echolocation ability of their predators. Echolocation research may ...
Cached Biology News:Solitary lemurs avoid danger with a little help from the neighbors 2UF researcher shows hawkmoths use ultrasound to combat bats 2UF researcher shows hawkmoths use ultrasound to combat bats 3
... KitTM allows graphic manipulation of DNA sequences ... an award winning interface design that allows ... to providing sophisticated drawing capabilities for Mac ... "Best Plasmid Mapping Software" by the Biotechnology ...
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
...
Biology Products: